Literature DB >> 30229527

A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy.

Pegah Jahangiri1, Kamyar Pournazari1, Drew A Torigian1, Thomas J Werner1, Samuel Swisher-McClure2, Charles B Simone3, Abass Alavi1.   

Abstract

PURPOSE: This prospective study assessed the feasibility of 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) to quantify radiation-induced lung inflammation in patients with locally advanced non-small cell lung cancer (NSCLC) who received radiotherapy (RT), and compared the differences in inflammation in the ipsilateral and contralateral lungs following proton and photon RT.
METHODS: Thirty-nine consecutive patients with NSCLC underwent FDG-PET/CT imaging before and after RT on a prospective study. A novel quantitative approach utilized regions of interest placed around the anatomical boundaries of the lung parenchyma and provided lung mean standardized uptake value (SUVmean), global lung glycolysis (GLG), global lung parenchymal glycolysis (GLPG) and total lung volume (LV). To quantify primary tumor metabolic response to RT, an adaptive contrast-oriented thresholding algorithm was applied to measure metabolically active tumor volume (MTV), tumor uncorrected SUVmean, tumor partial volume corrected SUVmean (tumor-PVC-SUVmean), and total lesion glycolysis (TLG). Parameters of FDG-PET/CT scans before and after RT were compared using two-tailed paired t-tests.
RESULTS: All tumor parameters after either proton or photon RT decreased significantly (p < 0.001). Among the 21 patients treated exclusively with proton RT, no significant increase in PVC-SUVmean or PVC-GLPG was observed in ipsilateral lungs after the PVC parameters of primary tumor were subtracted (p = 0.114 and p = 0.453, respectively). Also, there were no significant increases in SUVmean or GLG of contralateral lungs of patients who received proton RT (p = 0.841, p = 0.241, respectively). In contrast, among the nine patients who received photon RT, there was a statistically significant increase in PVC-GLPG of ipsilateral lung (p < 0.001) and in GLG of contralateral (p = 0.036) lung. In the subset of nine patients who received a combined proton and photon RT, there was a statistically significant increase in PVC-GLPG of ipsilateral lung (p < 0.001).
CONCLUSION: Our data suggest less induction of inflammatory response in both the ipsilateral and contralateral lungs of patients treated with proton compared to photon or combined proton-photon RT.

Entities:  

Keywords:  FDG-PET/CT; Lung cancer; Photon radiotherapy; Proton; Radiation pneumonitis

Mesh:

Substances:

Year:  2018        PMID: 30229527     DOI: 10.1007/s00259-018-4154-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  48 in total

1.  Challenges in defining radiation pneumonitis in patients with lung cancer.

Authors:  Zafer Kocak; Elizabeth S Evans; Su-Min Zhou; Keith L Miller; Rodney J Folz; Timothy D Shafman; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

2.  Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.

Authors:  Michael P Mac Manus; Zhe Ding; Annette Hogg; Alan Herschtal; David Binns; David L Ball; Rodney J Hicks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-02       Impact factor: 7.038

Review 3.  Prediction of radiation pneumonitis in lung cancer patients: a systematic review.

Authors:  Xiao-Jing Zhang; Jian-Guo Sun; Jie Sun; Hua Ming; Xin-Xin Wang; Lei Wu; Zheng-Tang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-29       Impact factor: 4.553

Review 4.  Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Joe Y Chang; Salma K Jabbour; Dirk De Ruysscher; Steven E Schild; Charles B Simone; Ramesh Rengan; Steven Feigenberg; Atif J Khan; Noah C Choi; Jeffrey D Bradley; Xiaorong R Zhu; Antony J Lomax; Bradford S Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-01-23       Impact factor: 7.038

Review 5.  The use of proton therapy in the treatment of lung cancers.

Authors:  Charles B Simone; Ramesh Rengan
Journal:  Cancer J       Date:  2014 Nov-Dec       Impact factor: 3.360

6.  Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.

Authors:  Geoffrey A Geiger; Miranda B Kim; Eric P Xanthopoulos; Daniel A Pryma; Surbhi Grover; John P Plastaras; Corey J Langer; Charles B Simone; Ramesh Rengan
Journal:  Clin Lung Cancer       Date:  2013-10-08       Impact factor: 4.785

7.  Mediastinal staging of non-small-cell lung cancer with positron emission tomography.

Authors:  R Chin; R Ward; J W Keyes; R H Choplin; J C Reed; S Wallenhaupt; A S Hudspeth; E F Haponik
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

8.  Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography.

Authors:  Deepak R Subramanian; Lee Jenkins; Ross Edgar; Nabil Quraishi; Robert A Stockley; David G Parr
Journal:  Am J Respir Crit Care Med       Date:  2012-07-26       Impact factor: 21.405

9.  Proton therapy radiation pneumonitis local dose-response in esophagus cancer patients.

Authors:  Alfredo E Echeverria; Matthew McCurdy; Richard Castillo; Vincent Bernard; Natalia Velez Ramos; William Buckley; Edward Castillo; Ping Liu; Josue Martinez; Thomas Guerrero
Journal:  Radiother Oncol       Date:  2012-11-02       Impact factor: 6.280

10.  Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study.

Authors:  Sarah Abdulla; Ali Salavati; Babak Saboury; Sandip Basu; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

View more
  7 in total

1.  The inflammatory response from stereotactic body proton therapy versus stereotactic body radiation therapy: implications from early stage non-small cell lung cancer.

Authors:  Xingzhe D Li; Charles B Simone
Journal:  Ann Transl Med       Date:  2019-12

2.  18F-FDG-PET/CT in the quantification of photon radiation therapy-induced vasculitis.

Authors:  Austin J Borja; Emily C Hancin; Alexandra D Dreyfuss; Vincent Zhang; Toby Mathew; Chaitanya Rojulpote; Thomas J Werner; Shivaraj Patil; Karthik Gonuguntla; Alexander Lin; Steven J Feigenberg; Samuel Swisher-McClure; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

3.  Design of a liver cancer-specific selector for the analysis of circulating tumor DNA.

Authors:  Yan Sun; Rui Meng; Heng Tang; Huimin Wang; Xueqin Guo; Yuanyuan Ma; Yun Yang; Xiaoming Wei; Feng Mu; Gang Wu; Jun Wang; Jun Liu; Mingshan Niu; Jun Xue
Journal:  Oncol Lett       Date:  2019-04-12       Impact factor: 2.967

4.  Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy.

Authors:  Linping Ke; Leilei Wu; Jinming Yu; Xue Meng
Journal:  Nucl Med Commun       Date:  2021-09-01       Impact factor: 1.698

5.  Diffuse FDG uptake in the bilateral lungs: hypersensitivity pneumonitis supported by low-dose CT findings.

Authors:  Shun Goto; Yohji Matsusaka; Tomohiko Yamane; Yuki Hoshino; Ichiei Kuji
Journal:  Asia Ocean J Nucl Med Biol       Date:  2022

6.  Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study.

Authors:  Linping Ke; Lu Wang; Jinming Yu; Xue Meng
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

7.  Risk factors for radiation-induced lung injury in patients with advanced non-small cell lung cancer: implication for treatment strategies.

Authors:  Sha Sha; Jigang Dong; Maoyu Wang; Ziyu Chen; Peng Gao
Journal:  World J Surg Oncol       Date:  2021-07-16       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.